Simple Rule to have an eye on this Stock: Urovant Sciences Ltd. (NASDAQ: UROV)

Urovant Sciences Ltd. (NASDAQ: UROV) spotted trading -31.35% off 52-week high price. On the other end, the stock has been noted 67.48% away from the low price over the last 52-weeks. The stock changed 2.24% to recent value of $10.97. The stock transacted 80773 shares during most recent day however it has an average volume of 72.43K shares. The company has 30.41M of outstanding shares and 4.45M shares were floated in the market.

Urovant Sciences (UROV) recently stated financial results for the three months and 2019 fiscal year ended March 31, 2020.

The fiscal fourth quarter of 2019 marked achievement of key milestones for Urovant Sciences, including publication of results from the international EMPOWUR Phase 3 pivotal trial and acceptance of the Company’s new drug application (NDA) for vibegron for the treatment of overactive bladder (OAB) by the U.S. Food and Drug Administration (FDA).

“The 2019 fiscal year and fourth quarter have been transformational for our company,” stated James Robinson, president and chief executive officer of Urovant Sciences. “With publication of data from the EMPOWUR study demonstrating that vibegron achieved statistical significance over placebo on both primary and all seven secondary endpoints, and FDA acceptance of our NDA, we look forward bringing to market a potentially best-in-class therapeutic option for the treatment of overactive bladder. Vibegron, if approved, could make a real difference in the lives of patients where there hasn’t been a new branded oral therapy released in nearly a decade and where patient dissatisfaction and unmet need remains high.”

Fourth Fiscal Quarter 2019 Financial Summary

For the quarter ended March 31, 2020, total operating expenses were $46.2M, comprised of research and development (R&D) expenses of $29.5M and general and administrative (G&A) expenses of $16.7M. Net loss for the quarter ended March 31, 2020 was $51.3M, or $1.68 per share. Cash used in operations was $31.6M. As of March 31, 2020, total cash was $51.4M.

Fiscal Year 2019 Financial Summary

For the fiscal year ended March 31, 2020, total operating expenses were $138.7M, comprised of R&D expenses of $92.4M and G&A expenses of $46.3M. Net loss for fiscal year 2019 was $146.7M, or $4.82 per share. Cash used in operations was $102.1M.

The price moved ahead of 10.20% from the mean of 20 days, 17.60% from mean of 50 days SMA and performed 2.96% from mean of 200 days price. Company’s performance for the week was -1.35%, 32.65% for month and YTD performance remained -29.27%.

 

Leave a Reply

Your email address will not be published. Required fields are marked *